WAM
NRXPW

Wolverine Asset Management’s NRX Pharmaceuticals Warrant NRXPW Stock Holding History

Wolverine Asset Management’s Portfolio NRXPW Stock Details NRXPW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$347 Buy
23,593
+1,300
+6% +$56 ﹤0.01% 1628
2025
Q4 		$1.58K Buy
22,293
+515
+2% +$51 ﹤0.01% 1550
2025
Q3 		$1.55K Hold
21,778
– – ﹤0.01% 1485
2025
Q2 		$1.85K Buy
21,778
+1,500
+7% +$121 ﹤0.01% 1484
2025
Q1 		$1.43K Buy
20,278
+15,088
+291% +$2.63K ﹤0.01% 1442
2024
Q4 		$664 Sell
5,190
-10,202
-66% -$634 ﹤0.01% 1532
2024
Q3 		$692 Buy
15,392
+500
+3% +$37 ﹤0.01% 1547
2024
Q2 		$895 Buy
14,892
+12,735
+590% +$1.6K ﹤0.01% 1546
2024
Q1 		$404 Sell
2,157
-5,500
-72% -$808 ﹤0.01% 1575
2023
Q4 		$993 Sell
7,657
-4,769
-38% -$460 ﹤0.01% 1611
2023
Q3 		$995 Buy
+12,426
New +$1.96K ﹤0.01% 1702

Wolverine Asset Management's NRXPW Position: Q1 2026 in Review

Wolverine Asset Management increased its NRX Pharmaceuticals Warrant (NRXPW) stake by 5.8% in Q1 2026, buying an estimated $56 and bringing the position to 23,593 shares worth $347. The position accounts for ﹤0.01% of the portfolio, ranked #1628.

Wolverine Asset Management first reported a position in NRXPW in Q3 2023 and has held it in 11 quarters since. The position peaked at $1.85K in Q2 2025. 2 funds tracked by Wall St. Rank hold NRXPW as of Q1 2026.

  • Wolverine Asset Management held 23,593 shares of NRX Pharmaceuticals Warrant worth $347 as of Q1 2026.
  • Wolverine Asset Management bought 1,300 NRX Pharmaceuticals Warrant shares in Q1 2026, an estimated $56.
  • NRX Pharmaceuticals Warrant made up ﹤0.01% of Wolverine Asset Management's portfolio in Q1 2026, its #1628 holding.
  • Wolverine Asset Management first reported a position in NRX Pharmaceuticals Warrant in Q3 2023 and has held it in 11 quarters since.
  • Wolverine Asset Management's NRX Pharmaceuticals Warrant position peaked at $1.85K in Q2 2025.
  • 2 funds tracked by Wall St. Rank held NRX Pharmaceuticals Warrant as of Q1 2026.

Based on Wolverine Asset Management's 13F filing for Q1 2026, filed 4 May 2026.